A

113.77

-0.97%↓

VEEV

172.52

-1.27%↓

HQY

80.96

-2.52%↓

PHR.US

9.06

+0.33%↑

CSBR

5.85

+1.39%↑

A

113.77

-0.97%↓

VEEV

172.52

-1.27%↓

HQY

80.96

-2.52%↓

PHR.US

9.06

+0.33%↑

CSBR

5.85

+1.39%↑

A

113.77

-0.97%↓

VEEV

172.52

-1.27%↓

HQY

80.96

-2.52%↓

PHR.US

9.06

+0.33%↑

CSBR

5.85

+1.39%↑

A

113.77

-0.97%↓

VEEV

172.52

-1.27%↓

HQY

80.96

-2.52%↓

PHR.US

9.06

+0.33%↑

CSBR

5.85

+1.39%↑

A

113.77

-0.97%↓

VEEV

172.52

-1.27%↓

HQY

80.96

-2.52%↓

PHR.US

9.06

+0.33%↑

CSBR

5.85

+1.39%↑

Search

Medtronic PLC

Uždarymo kaina

SektoriusSveikatos priežiūra

86.38 0.14

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

85.33

Max

86.94

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-231M

1.1B

Pardavimai

57M

9B

P/E

Sektoriaus vid.

24.101

66.418

Pelnas, tenkantis vienai akcijai

1.36

Dividendų pajamingumas

3.27

Pelno marža

12.675

Darbuotojai

95,000

EBITDA

124M

2.5B

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+26.02% upside

Dividendai

By Dow Jones

Dividendų pajamingumas

Sektoriaus vid.

3.27%

2.36%

Kitas uždarbis

2026-05-20

Kitas dividendų mokėjimo data

2026-04-17

Kita Ex Dividend data

2026-06-26

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-17B

111B

Ankstesnė atidarymo kaina

86.24

Ankstesnė uždarymo kaina

86.38

Naujienos nuotaikos

By Acuity

31%

69%

37 / 349 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Weak Bearish Evidence

Medtronic PLC Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-03-10 11:19; UTC

Įsigijimai, susijungimai, perėmimai

Medtronic to Buy Scientia Vascular in $550 Million Deal

2026-02-17 12:43; UTC

Uždarbis

Medtronic 3Q Profit Falls Despite Higher Revenue

2026-02-03 13:53; UTC

Įsigijimai, susijungimai, perėmimai

Medtronic to Acquire CathWorks in Deal Valued Up to $585 Million

2026-03-24 20:59; UTC

Uždarbis

Medtronic PLC Cuts FY26 View To Adj EPS $5.50-Adj EPS $5.54 >MDT

2026-03-10 10:46; UTC

Įsigijimai, susijungimai, perėmimai

Medtronic: Scientia Deal Complements Neurovascular Portfolio >MDT

2026-03-10 10:46; UTC

Įsigijimai, susijungimai, perėmimai

Medtronic: Scientia Deal Includes Potential Undisclosed Earn-Out, Milestone Payments >MDT

2026-03-10 10:45; UTC

Įsigijimai, susijungimai, perėmimai

Medtronic: Scientia Vascular Acquisition Valued at $550 Million >MDT

2026-03-10 10:45; UTC

Įsigijimai, susijungimai, perėmimai

Medtronic to Acquire Scientia Vascular >MDT

2026-02-17 21:21; UTC

Uždarbis

These Stocks Are Today's Movers: Paramount, Masimo, Medtronic, Kyndryl, eToro, Genuine Parts, Southwest, and More -- Barrons.com

2026-02-17 18:11; UTC

Uždarbis

Medtronic Posts Better-Than-Expected Earnings. Here's Why the Stock Is Falling. -- Barrons.com

2026-02-17 14:48; UTC

Uždarbis

Medtronic Posts Better-Than-Expected Earnings. Here's Why the Stock Is Falling. -- Barrons.com

2026-02-17 13:00; UTC

Uždarbis

Medtronic Posts Better-Than-Expected Earnings. Here's Why the Stock Is Falling. -- Barrons.com

2026-02-17 12:05; UTC

Uždarbis

Medtronic Posts Better-Than-Expected Earnings. Here's Why the Stock Is Falling. -- Barrons.com

2026-02-17 11:47; UTC

Uždarbis

Medtronic Sees 2026 EPS up 4.5%, Excluding Potential Impact From Tariffs >MDT

2026-02-17 11:47; UTC

Uždarbis

Medtronic Still Sees FY26 Organic Revenue Up About 5.5% >MDT

2026-02-17 11:46; UTC

Uždarbis

Medtronic FY26 View Includes Potential Impact From Tariffs of About $185M >MDT

2026-02-17 11:46; UTC

Uždarbis

Medtronic Backs FY26 View of Adj EPS $5.62-Adj EPS $5.66 >MDT

2026-02-17 11:46; UTC

Uždarbis

Medtronic Reiterates FY26 Organic Rev Growth, EPS Guidance >MDT

2026-02-17 11:45; UTC

Uždarbis

Medtronic 3Q Adj EPS $1.36 >MDT

2026-02-17 11:45; UTC

Uždarbis

Medtronic 3Q Neuroscience Portfolio Rev $2.56B >MDT

2026-02-17 11:45; UTC

Uždarbis

Medtronic 3Q Organic Revenue Up 6.0% >MDT

2026-02-17 11:45; UTC

Uždarbis

Medtronic 3Q Sales $9.02B >MDT

2026-02-17 11:45; UTC

Uždarbis

Medtronic 3Q Diabetes Rev $796M >MDT

2026-02-17 11:45; UTC

Uždarbis

Medtronic 3Q Cardiovascular Portfolio Rev $3.46B >MDT

2026-02-17 11:45; UTC

Uždarbis

Medtronic 3Q Medical Surgical Portfolio Rev $2.17B >MDT

2026-02-17 11:45; UTC

Uždarbis

Medtronic 3Q Net $1.14B >MDT

2026-02-17 11:45; UTC

Uždarbis

Medtronic 3Q EPS 89c >MDT

2026-02-17 09:53; UTC

Karštos akcijos

Stocks to Watch Tuesday: Norwegian, Hyatt, Zim, Medtronic -- WSJ

2026-02-03 13:38; UTC

Įsigijimai, susijungimai, perėmimai

Medtronic to Acquire CathWorks in Deal Valued Up to $585M

2026-02-03 13:21; UTC

Įsigijimai, susijungimai, perėmimai

Medtronic Sees Deal Neutral to Accretive Thereafter >MDT

Akcijų palyginimas

Kainos pokytis

Medtronic PLC Prognozė

Kainos tikslas

By TipRanks

26.02% į viršų

12 mėnesių prognozė

Vidutinis 109.17 USD  26.02%

Aukščiausias 125 USD

Žemiausias 86 USD

Remiantis 21 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Medtronic PLC kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

21 ratings

13

Pirkti

8

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

83.26 / 84.875Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Weak Bearish Evidence

Vidutinės trukmės periodas

Bullish Evidence

Ilgalaikis periodas

Bearish Evidence

Rinkos nuotaikos

By Acuity

37 / 349 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Bulių rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Aukščiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Medtronic PLC

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and other products. The Neuroscience Portfolio segment offers medical devices and implants, biologic solutions, spinal cord stimulation and brain modulation systems, implantable drug infusion systems, and interventional products, as well as nerve ablation system under the Accurian name. The segment offers its products for spinal surgeons, neurosurgeons, neurologists, pain management specialists, anesthesiologists, orthopedic surgeons, urologists, urogynecologists, and interventional radiologists, as well as ear, nose, and throat specialists; and energy surgical instruments. The Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure and electrosurgery products, AI-powered surgical video and analytics platform, robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology products, gastrointestinal and hepatologic diagnostics and therapies, and therapies to treat other non-exclusive diseases and conditions; and patient monitoring and airway management products. The Diabetes Operating Unit segment provides insulin pumps and consumables, continuous glucose monitoring systems, and InPen, a smart insulin pen system. The company was founded in 1949 and is headquartered in Galway, Ireland.
help-icon Live chat